Prospects for Minimal Residual Disease as a Surrogate Endpoint in Pediatric Acute Lymphoblastic Leukemia Clinical Trials-Reference-Cited by-同舟云学术

Prospects for Minimal Residual Disease as a Surrogate Endpoint in Pediatric Acute Lymphoblastic Leukemia Clinical Trials

Published:2018-10-01 Issue:4 Volume:2 Page:
ISSN:2515-5091
Container-title:JNCI Cancer Spectrum
language:en
Short-container-title:

Author:

McShane Lisa M¹,Smith Malcolm A²

Affiliation:

1. Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Biometric Research Program

2. Cancer Therapy Evaluation Program, Bethesda, MD

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jncics/article-pdf/2/4/pky070/28907834/pky070.pdf

Reference8 articles.

1. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis;Berry;JAMA Oncol,2017

2. Minimal residual disease is an independent predictor for 10-year survival in CLL;Kwok;Blood,2016

3. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis;Munshi;JAMA Oncol,2017

4. Validation of minimal residual disease as surrogate endpoint for event-free-survival in childhood acute lymphoblastic leukemia;Galimberti;JNCI Cancer Spectr,2018

5. Surrogate end points in clinical trials: are we being misled?;Fleming;Ann Intern Med,1996

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Flow Cytometry-Based Detection of Minimal/Measurable Residual Disease Predicts Survival Outcomes in Pediatrics, Adolescents, and Young Adults With T-acute Lymphoblastic Leukemia;Cureus;2024-06-05

2. Post-induction Measurable Residual Disease Using Multicolor Flow Cytometry Is Strongly Predictive of Inferior Clinical Outcome in the Real-Life Management of Childhood T-Cell Acute Lymphoblastic Leukemia: A Study of 256 Patients;Frontiers in Oncology;2020-04-24